QURE

시간 외 거래: 5.76

Uniqure N V (QURE)

Relative Volume:

Uniqure N V Stock (QURE) Company Profile

1-339-970-7000

PAASHEUVELWEG 25A, AMSTERDAM

최신 SEC 제출 서류

QURE's Discussions on Twitter

Uniqure N V Stock (QURE) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2022-03-17	업그레이드	UBS	Neutral → Buy
2021-06-15	개시	BTIG Research	Buy
2021-05-21	개시	UBS	Neutral
2021-04-26	재개	Credit Suisse	Outperform
2021-04-01	업그레이드	Mizuho	Neutral → Buy
2021-01-07	업그레이드	Guggenheim	Neutral → Buy
2020-11-24	개시	H.C. Wainwright	Buy
2020-11-11	개시	Berenberg	Buy
2020-11-09	개시	Jefferies	Buy
2020-11-04	개시	Cantor Fitzgerald	Overweight
2020-10-23	개시	RBC Capital Mkts	Outperform
2020-08-25	개시	Raymond James	Strong Buy
2020-07-31	업그레이드	Robert W. Baird	Neutral → Outperform
2020-06-25	다운그레이드	Mizuho	Buy → Neutral
2020-06-25	다운그레이드	Robert W. Baird	Outperform → Neutral
2020-06-25	다운그레이드	Wells Fargo	Overweight → Equal Weight
2019-12-03	개시	Cowen	Outperform
2019-12-03	개시	Goldman	Buy
2019-11-05	개시	Credit Suisse	Outperform
2019-10-11	개시	Stifel	Buy
2019-09-25	개시	Bernstein	Outperform
2019-09-12	개시	Mizuho	Buy
2019-07-30	다운그레이드	Guggenheim	Buy → Neutral
2019-07-08	재확인	Cantor Fitzgerald	Overweight
2019-04-12	개시	Piper Jaffray	Overweight
2019-03-29	개시	Robert W. Baird	Outperform

Uniqure N V 주식(QURE)의 최신 뉴스

Uniqure N V (QURE) 재무 분석

Uniqure N V (QURE)

Uniqure N V Stock (QURE) Company Profile

Uniqure N V Stock (QURE) Upgrades & Downgrades

Uniqure N V 주식(QURE)의 최신 뉴스

Acadian Asset Management LLC Reduces Holdings in uniQure (NASDAQ:QURE) - MarketBeat

(QURE) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Acadian Asset Management LLC Has $2.30 Million Position in uniQure (NASDAQ:QURE) - Defense World

uniQure (NASDAQ:QURE) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

Institutional owners may take dramatic actions as uniQure N.V.'s (NASDAQ:QURE) recent 11% drop adds to one-year losses - Simply Wall St

Gene Therapy Market Size to Reach USD 54.39 Billion By 2032 with CAGR of 23.12%, Boosted by Rising Genetic Disorders and Advances in CRISPR Technology - GlobeNewswire Inc.

Trading (QURE) With Integrated Risk Controls - Stock Traders Daily

uniQure N.V.’s Banking’s 100-Day Moving Average at 5.76: Will the Stock Break Through? - The InvestChronicle

Assenagon Asset Management S.A. Makes New Investment in uniQure (NASDAQ:QURE) - MarketBeat

uniQure Forecasted to Post FY2024 Earnings of ($4.84) Per Share (NASDAQ:QURE) - MarketBeat

FY2024 Earnings Forecast for uniQure Issued By HC Wainwright (NASDAQ:QURE) - Defense World

uniQure retains PT with Buy rating on gene therapy prospects - Investing.com

HC Wainwright Reaffirms "Buy" Rating for uniQure (NASDAQ:QURE) - MarketBeat

HC Wainwright Reaffirms “Buy” Rating for uniQure (NASDAQ:QURE) - Defense World

Is uniQure N.V. (QURE) worth investing in despite its undervalued state? - US Post News

QURE (uniQure NV) Cash From Other Investing Activities : $-366.44 Mil (TTM As of Jun. 2024) - GuruFocus.com

QURE (uniQure NV) Total Inventories : $0.00 Mil (As of Jun. 2024) - GuruFocus.com

uniQure NV (STU:UQ1) 3-Year EPS without NRI Growth Rate : -36.20% (As of Jun. 2024) - GuruFocus.com

QURE (uniQure NV) Change In Receivables : $90.64 Mil (TTM As of Jun. 2024) - GuruFocus.com

Vanguard Group Inc. Raises Position in uniQure (NASDAQ:QURE) - MarketBeat

Vanguard Group Inc. Acquires 109,740 Shares of uniQure (NASDAQ:QURE) - Defense World

uniQure (NASDAQ:QURE) Short Interest Up 20.1% in July - MarketBeat

uniQure NV (STU:UQ1) Inventory-to-Revenue : 0.68 (As of Jun. 2024) - GuruFocus.com

uniQure NV (STU:UQ1) Financial Strength : 4 (As of Jun. 2024) - GuruFocus.com

uniQure Begins Phase I/IIa Trial for Fabry Disease Treatment - TipRanks

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease - GlobeNewswire

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease - StockTitan

Analysts Set uniQure (NASDAQ:QURE) Price Target at $18.60 - MarketBeat

uniQure (NASDAQ:QURE) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World

Implied Volatility Surging for uniQure (QURE) Stock Options - Yahoo Singapore News

Cantor Fitzgerald Weighs in on uniQure's FY2024 Earnings (NASDAQ:QURE) - MarketBeat

uniQure (NASDAQ:QURE) Expected to Earn FY2024 Earnings of ($3.14) Per Share - Defense World

StockNews.com Upgrades uniQure (NASDAQ:QURE) to “Sell” - Defense World

How to Take Advantage of moves in (QURE) - Stock Traders Daily

uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity (QURE) - Seeking Alpha

uniQure (NASDAQ:QURE) Upgraded to "Sell" by StockNews.com - MarketBeat

Leerink Partnrs Comments on uniQure's Q3 2025 Earnings (NASDAQ:QURE) - MarketBeat

Analysts Offer Predictions for uniQure’s Q3 2025 Earnings (NASDAQ:QURE) - Defense World

The Goldman Sachs Group Increases uniQure (NASDAQ:QURE) Price Target to $10.00 - Defense World

uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Simply Wall St

uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo Finance

UniQure to cut 65% of workforce, or 300 jobs, in major restructuring (NASDAQ:QURE) - Seeking Alpha

uniQure (NASDAQ:QURE) PT Raised to $10.00 at The Goldman Sachs Group - MarketBeat

UniQure Keeps Cutting Costs With 300 More Jobs To Go - Scrip

UniQure: Q2 Earnings Snapshot - Darien Times

UniQure: Q2 Earnings Snapshot - San Antonio Express-News

UniQure: Q2 Earnings Snapshot - New Haven Register

UniQure: Q2 Earnings Snapshot - The Advocate

UniQure: Q2 Earnings Snapshot - The Washington Post

UniQure: Q2 Earnings Snapshot - San Francisco Chronicle

UniQure (QURE) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance

Uniqure N V (QURE) 재무 분석

매출

순이익

현금흐름

주당 순 이익

QURE과 유사한 종목